Competitive Salary: EMBL: Project Leader - Model Organism Genomics Location: Cambridge, Cambridgeshire, England

Notice NOT-AA-19-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The PE-CGS Network will include: Several U2C Research Centers (to be supported under this FOA); and One U24 Coordinating Center (to be supported under companion RFA-CA-19-046). The overall purpose of the PE-CGS Network is twofold: To promote and support research on direct participant* engagement approaches; and Use such approaches for rigorous cancer genome sequencing projects addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. *Note: For this FOA, study participant denotes cancer patients and/or post-treatment cancer survivors. Each PE-CGS U2C Research Center to be proposed in response to this FOA must consist of the following components: Administrative Core Participant Engagement Unit; Genome Characterization Unit; and Engagement Optimization Unit. In addition to conducting individual projects, PE-CGS U2C Research Centers will be expected to operate as a collaborative network. Various trans-network activities will be facilitated by the PE-CGS Network Coordinating Center (U24).

Funding Opportunity RFA-CA-19-046 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The PE-CGS Network will include: Several U2C Research Centers (to be supported under companion RFA-CA-19-045); and One U24 Coordinating Center (to be supported under this FOA). The overall purpose of the PE-CGS Network is twofold: To promote and support research on direct participant* engagement approaches; and Use such approaches for rigorous cancer genome sequencing projects addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. *Note: For this FOA, study participant denotes cancer patients and/or post-treatment cancer survivors. PE-CGS U2C Research Centers, together with the PE-CGS U24 Coordinating Center, will form a collaborative Network. The PE-CGS U24 Coordinating Center will have three major areas of responsibility: (1) Network Coordination; (2) Network Outreach and Promotion; and (3) Network Best Practices.

Notice NOT-AG-19-026 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-025 from the NIH Guide for Grants and Contracts

Notice NOT-ES-19-016 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-029 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-20-007 from the NIH Guide for Grants and Contracts. The primary focus of this FOA is to promote studies which apply state-of-the art concepts, technologies, and methodologies in the stem cell field to better understand how stem cells function within diseased or damaged gynecologic tissues. For the purposes of this announcement, the gynecologic disorders of interest are limited to uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse. These disorders have been chosen based on their prevalence, high associated morbidity, high branch priority, and substantial costs to the healthcare system. The ultimate goal of this initiative is to improve womens gynecologic health by accelerating our understanding of the role of pluripotent progenitor/stem cells in the initiation, progression and severity of these gynecologic disorders in order to inform the development of effective prevention, diagnostic, and therapeutic strategies.

Notice NOT-OD-19-122 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-127 from the NIH Guide for Grants and Contracts

Notice NOT-RM-19-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-064 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-048 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-325 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Notice NOT-GM-19-054 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-021 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Support Bioinformatician - 6 Month Contract London To build on the success of the 100,000 Genomes Project, the Government tasked NHS England with sup London, England

Competitive Salary: EMBL: Postdoctoral fellow Location: EM Cambridge, Cambridgeshire, England

Funding Opportunity PAR-19-319 from the NIH Guide for Grants and Contracts. The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.